Blockchain

Nubila Kickstarts Fundraising Round Led by IoTeX, VeChain and Other Leading Investors

San Francisco, United States, July 1st, 2024, Chainwire

 

Nubila, a leading data oracle specializing in accurate and actionable Environmental, Social, and Governance (ESG) data for the Decentralized Physical Infrastructure Network (DePIN) ecosystem, has kicked off its fundraising round. The on-going round is led by IoTeX and VeChain + Boston Consulting Group, with the participation from OrangeDAO, MH Ventures, Future Money Group, SNZ Capital, DePINsurf, Kronos Research, Taisu Ventures, Bytetrade, WaterDrip, Deepin Lab, Assembly Partners, Cyber, Radiance Ventures and Genopets, Nubila has raised $2.5 million to date.

This significant investment underscores the industry’s recognition of Nubila’s potential to leverage AI and tokenization to empower decision-making, drive sustainable development, and build financial products with ESG data.

“At Nubila, we are committed to building the infrastructure for the MachineFi revolution, serving as the ‘data sensor layer’ for our planet,” said Ben, the founder of Nubila. “Our vision is to create a comprehensive network of advanced weather stations and sensors that capture critical environmental data. Integrating real-time ESG data into an increasing number of AI models, such as Microsoft’s recently released Aurora atmospheric model, will enhance ESG assessments and drive more informed and sustainable decision-making across industries. With this funding, we are poised to scale our operations and expand our global reach, ensuring that we contribute significantly to the sustainability and well-being of our planet.”

The funds will be strategically used to scale Nubila’s operations, further develop its cutting-edge ESG Data Oracle, and pursue key strategic goals. These initiatives include enhancing data accuracy, expanding the network’s reach, increasing user engagement, and the awareness of sustainability investment.

“Nubila is at the forefront of leveraging DePIN and AI to transform ESG data management,” said Raullen Chai, Founder of IoTeX. “Their approach to creating a decentralized ESG network of community-owned IoT devices, delivering hyperlocal weather data to enhance predictions for various industries is revolutionary. By providing actionable environmental data, Nubila is not only enhancing ESG assessments but also enabling more informed and sustainable decision-making across various industries. We are excited to support their mission and look forward to seeing the significant impact they will make on the sustainability landscape.”

This network features advanced weather stations, the only ones equipped with high-precision sensors and cameras, dedicated to gathering detailed environmental data for accurate ESG assessments. To date, Nubila has deployed 16,000 stations worldwide, collectively capturing over 100TB in weather data.

About Nubila

Headquartered in San Francisco, Nubila is a pioneer in the Environmental, Social, and Governance (ESG) data sector, dedicated to transforming sustainability initiatives through innovative solutions. By building the largest ESG Data Oracle within the DePIN ecosystem, Nubila leverages AI and ESG tokenization to empower decision-making, drive sustainable development and build financial products.

 

Contact

Marketing Head
Darren Goh
Nubila
[email protected]

PostAd_coinrule_banner728x90

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Equasens: 2024 half-year results

2024-09-27T16:00:00Z

Villers-lès-Nancy, 27 September 2024 - 6:00 p.m. (CET)

PRESS RELEASE

2024 half-year results

  • Group results impacted by weaker economic conditions and continuing investment efforts in H1:
    • Revenue: €108.0m, -4.1%
    • Current Operating Income: €20.9m, -24.1%
  • Net Profit attributable to the Group: €17.2m, -21.8%
  • Though with a profit margin that continues to be very positive:
    • Ratio of Current Operating Income (COI) to Sales: 19.3% on a reported basis and 20.0% like-for-like
H1 RESULTS (€M)2023
reported basis
2024
reported basis
Change / Reported basisExternal growthChange / Like-for-like basis
Revenue112.6108.0-4.6-4.1%-3.7-8.3-7.4%
Current operating income (COI)27.520.9-6.6-24.1%0.0-6.7-24.3%
Net Profit22.918.1-4.8-21.0%0.0-4.8-21.1%
Net Profit attributable to the Group22.017.2-4.8-21.8%   

The financial statements for the six-month period ended 30 June 2024 were reviewed and adopted by EQUASENS' Board of Directors, chaired by Thierry Chapusot, on 27 September 2024. These interim consolidated financial statements were subject to a limited review by the Statutory Auditors.

_____

Results at 30 June 2024

H1 Current Operating Income / Division2023
reported basis
2024
reported basis
Change / Reported basisExternal growthChange / Like-for-like basis
Pharmagest18.414.1-4.3-23.5%-0.1-4.4-24.0%
Axigate Link4.64.4-0.2-4.9% -0.2-4.9%
e-Connect3.62.5-1.1-29.9% -1.1-29.9%
Medical Solutions1.30.0-1.3-100.0%0.1-1.2-92.5%
Fintech-0.4-0.10.369.3% 0.3-69.3%
Current Operating Income27.520.9-6.6-24.1%0.0-6.7-24.3%
  • PHARMAGEST division: a contraction in earnings reflecting lower sales and reinforced teams in Europe (COI/Sales: 17.2%)

The decline in the Division's operating income is mainly attributable to a reduction in sales in France in the configuration and hardware segment. In a persistently challenging economic environment, the Division continued to focus its commercial strategy on acquiring new customers and regularly rolling out new software and hardware solutions.
Despite this, recurring revenues were bolstered by the combined contribution of new SaaS offerings and contract indexation.
To accelerate the deployment of solutions in Europe, the R&D and sales teams continued to be strengthened.

  • AXIGATE LINK division: the profit margin remains high (COI/Sales: 28.6%)

Strategic investments to support the roll-out of SaaS solutions such as TitanLink for Nursing Homes in Europe, and the extension of homecare services, have temporarily weighed on the Division's results.

  • E-CONNECT division: current operating income declined in response to lower sales (COI/Sales: 45.4%)

As previously reported, H1 2023 sales and earnings were boosted by the announced discontinuation of sales of Application Reader Terminals.
The downturn in business in the first half of 2024 thus reflected the corresponding decline in sales.
Despite this unfavourable environment, the Division demonstrated its ability to adapt by maintaining a healthy profit margin based on tight cost controls.

  • MEDICAL SOLUTIONS division: a year of transition between the Ségur digital healthcare investment programme and a new software solution (COI/Sales: -)

Preparations for the Division's future involving the development of a new software platform and optimising the sales organisation led to significant investments which, in conjunction with lower sales following the end of the Ségur programme roll-out, weighed on the Division's results. Recurring revenues rose 13.7%, resulting in a gross margin of 72.8%.

  • FINTECH division: efforts to stabilise the business paid off in H1, with an improvement in earnings of €0.3m (COI/Sales: -)

Consolidated balance sheet highlights

  • Cash flow after interest and tax maintained a positive trend at €20.8m.
  • Financial investments, through acquisitions as well as capital expenditures, in particular for the EQUASENS private healthcare cloud, continued, with more than €16.0m committed in H1.
  • The net financial surplus at 30/06/2024 of €87.9m takes into account a change in presentation of IFRS 16 lease liabilities and put options for minority shareholders of €10.8m (recognised under other liabilities versus financial liabilities previously).

2024 outlook

  • The Group maintains its forecast for a return to revenue growth starting in the second half of 2024, and an acceleration in 2025 driven by current investments and an economic climate that looks set to improve, particularly for pharmacies in France.
  • The Group will continue to invest in R&D, infrastructure and sales forces in France and Europe in the second half of 2024. And while this will have a temporary impact on profitability in 2024, it should generate a return on investment from 2025 onwards.
  • With a strategy focused on patients and interoperability, the Group is ideally positioned to seize opportunities for external growth in France and Europe.

Financial calendar:

  • 1 October 2024: Presentation of H1 2024 results
  • 7 November 2024: Publication of Q3 2024 revenue
  • 6 February 2025: Publication of f Q4/FY 2024 revenue

About Group Equasens

With more than 1,300 employees, Equasens Group is today a key player in the European healthcare sector, providing software and hardware solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, hospital-at-home programmes, retirement homes, health centres) in both primary and secondary care sectors.

With operations in in France, Germany, Great Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group today brings together healthcare professionals within a unique ecosystem in France and Europe benefiting people by making available the very best of technology.

Listed on Euronext Paris™ - Compartment B

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).
ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about Equasens Group www.equasens.com and on LinkedIn

CONTACTS

Analyst and Investor Relations:
Chief Administrative and Financial Officer: Frédérique Schmidt
Tel: +33 (0)3 83 15 90 67 - [email protected]

Financial communication agency:
FIN’EXTENSO - Isabelle Aprile

Tel.: +33 (0)6 17 38 61 78 - [email protected]

Attachment


GlobeNewsWire News

Recent Comments